-
Xencor, Inc. has reported its second-quarter 2026 results, with net loss improving to US$21.73 million versus US$30.83 million a year earlier, while basic and diluted loss per share from continuing operations narrowed to US$0.29 from US$0.41.
-
Over the first half of 2026, however, Xencor’s net loss widened to US$150.65 million and loss per share to US$1.99, highlighting a tension between short-term quarterly progress and heavier year-to-date spending.
-
We’ll now consider how this quarterly loss improvement, against a larger first-half deficit, reshapes Xencor’s investment narrative and risk profile.
AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.
Xencor Investment Narrative Recap
To own Xencor, you need to believe its TL1A and bispecific antibody platform will eventually justify ongoing losses and heavy R&D. The latest Q2 numbers modestly ease short term earnings pressure, but the sharply higher first half loss keeps funding needs and trial execution as the key near term catalyst and the biggest risk. On balance, this earnings print does not materially change that trade off, but it does sharpen focus on how tightly costs are managed into late stage trials.
The most relevant recent update here is the May 2026 XmAb942 program news, with Phase 2b XENITH UC now underway and an interim blinded analysis expected around year end 2026. That study is a central value driver for Xencor, and the widened first half loss underlines how dependent the story is on hitting those clinical milestones on time and without major safety or efficacy surprises, given the company remains unprofitable and is investing heavily in TL1A assets.
Yet even as Q2 losses eased, the scale of first half spending raises questions investors should be aware of about how long Xencor can fund its trials without…
Read the full narrative on Xencor (it’s free!)
Xencor’s narrative projects $148.2 million revenue and $28.2 million earnings by 2029. This requires 15.0% yearly revenue growth and an earnings increase of about $200.6 million from -$172.4 million today.
Uncover how Xencor’s forecasts yield a $28.50 fair value, a 37% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were already assuming revenue might fall about 11.7 percent a year and still saw Xencor needing very high future profit margins to justify a US$14.00 target price, which is far more pessimistic than consensus and could look different once this Q2 loss trend and your chosen risk around funding constraints are fully reflected.
